Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Not for distribution to United States news wire services or for dissemination in the United States
TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX:MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement (the “Offering”). Medicenna intends to use the net proceeds from the Offering for further development of its MDNA11 program, advancement of its preclinical programs and general corporate purposes.
Related news for (MDNAF)
- Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
- Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
- Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
- Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
- Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe